Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : National Institute of Pharmacy and Nutrition
Deal Size : Inapplicable
Deal Type : Inapplicable
Egis Favipiravir Drug Licenced for Covid-19 Treatment
Details : The active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licenced for treatment of Covid-19 by the National Institute of Pharmacy and Nutrition (OGYÉI).
Product Name : Favipiravir-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : National Institute of Pharmacy and Nutrition
Deal Size : Inapplicable
Deal Type : Inapplicable
KEY PRODUCTS
Reset All
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
